When I read the news that three out of four manufacturers of asthma and COPD inhalers have decided to cap the price to the ...
When PBMs refuse to cover the cheaper generic, patients are left on the hook for the full cost. Insurers and employers hire ...
Sanders and other lawmakers in January criticized four makers of inhalers sold in the U.S. — AstraZeneca, Boehringer ... In March, three of the four companies decided to cap inhaler costs at $35 each.
Toward the end of March, GSK followed in the footsteps of Boehringer Ingelheim and AstraZeneca when it pledged to cap out-of-pocket costs for its inhalers at $35 per month by Jan. 1, 2025. Aside from ...
In response to the FTC’s November challenges, Kaleo, Impax Labs, GSK delisted patents, and AstraZeneca, Boehringer Ingelheim, ...
Less than two months after GlaxoSmithKline pledged to cap out-of-pocket costs, Sen. Maggie Hassan (D-N.H.) is accusing the ...
The move targets over 300 listings for 20 branded products from companies such as AstraZeneca, Novo Nordisk, and GSK that the ...
The move broadens the antitrust regulator’s campaign against allegedly “improper or inaccurate” patent listings by drugmakers to include top-selling medicines for weight loss, diabetes, asthma and ...
Boehringer Ingelheim, GSK, Novartis, Teva, and Covis Pharma have been taken to task for asthma and COPD inhalers, while ...
The US Federal Trade Commission has accused 10 multinational pharmaceutical manufacturers, including GSK, of blocking the ...
The FTC has sent warning letters to 10 drugmakers, including Novo Nordisk (NVO), Teva (TEVA) and AstraZeneca (AZN) over ...
Shortly afterward, three of the biggest makers of asthma inhalers, including GSK, pledged to cap out-of-pocket costs for some ... are Boehringer Ingelheim and AstraZeneca. Organon told CNN it ...